Related Experiment Videos
Neonatal deaths after hepatitis B vaccine: the vaccine adverse event reporting system, 1991-1998
M T Niu1, M E Salive, S S Ellenberg
1Division of Biostatistics and Epidemiology, Center for Biologic Evaluation and Research, US Food and Drug Administration, Rockville, MD 20852-1448, USA. niu@cber.fda.gov
Objective:
To evaluate reports of neonatal deaths (aged 0-28 days) after hepatitis B (HepB) immunization reported to the national Vaccine Adverse Event Reporting System (VAERS).
Design:
Case series; review of autopsy reports.
Setting:
Voluntary reports submitted to VAERS, a passive surveillance system, from the US population.
Patients:
All US neonates (0-28 days of age) whose deaths after HepB vaccination given alone were reported to VAERS, occurring from January 1, 1991, through October 5, 1998.
Intervention:
None (observational database).
Results:
Of 1771 neonatal reports, there were 18 deaths in 8 boys and 9 girls (1 patient unclassified). The mean age at vaccination for these 18 cases was 12 days (range, 1-27 days); median time from vaccination to onset of symptoms was 2 days (range, 0-20 days); and median time from symptoms to death was 0 days (range, 0-15 days). The mean birth weight of the neonates (n = 15) was 3034 g (range, 1828-4678 g). The causes of death for the 17 autopsied cases were sudden infant death syndrome for 12, infection for 3, and 1 case each of intracerebral hemorrhage, accidental suffocation, and congenital heart disease.
Conclusion:
Few neonatal deaths following HepB vaccination have been reported, despite the use of at least 86 million doses of pediatric vaccine given in the United States since 1991. While the limitations of passive surveillance systems do not permit definitive inference, these data suggest that HepB immunization is not causing a clear increase in neonatal deaths.